NASDAQ:SLS

SELLAS Life Sciences Group Stock Forecast, Price & News

$8.45
+0.24 (+2.92 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.17
Now: $8.45▼
$8.53
50-Day Range
$7.89
MA: $9.09▼
$11.71
52-Week Range
$1.61
Now: $8.45▼
$19.38
Volume204,385 shs
Average Volume1.74 million shs
Market Capitalization$127.47 million
P/E RatioN/A
Dividend YieldN/A
Beta2.13
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It also develops nelipepimut-S, a cancer immunotherapy that is in Phase 2b clinical trials for the treatment of early stage breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SLS
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.sellaslifesciences.com
Phone917 438 4353
Employees7
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio2.21
Quick Ratio2.21

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.20 per share
Price / Book7.04

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-19,290,000.00
Net MarginsN/A
Return on Equity-316.15%
Return on Assets-122.78%

Miscellaneous

Outstanding Shares15,085,000
Market Cap$127.47 million
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable

Headlines

Shareholders Are Raving About How The SELLAS Life Sciences Group (NASDAQ:SLS) Share Price Increased 349%
March 25, 2021 |  finance.yahoo.com
SELLAS Life Sciences to Participate in the M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference on March 17th
March 11, 2021 |  finance.yahoo.com
SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones
January 14, 2021 |  finance.yahoo.com
SELLAS Life Sciences Group, Inc. (SLS)
January 6, 2021 |  finance.yahoo.com
SELLAS Announces Promising Initial Clinical Data for Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors in Two Solid Tumor Indications
December 21, 2020 |  finance.yahoo.com
SELLAS Strengthens Year-End Balance Sheet with Addition of Approximately $30.5 Million
December 17, 2020 |  finance.yahoo.com
News for SELLAS Life Sciences Group Inc Registered Shs
December 13, 2020 |  markets.businessinsider.com
SELLAS Announces Pricing of $16.2 Million Registered Direct Offering
December 13, 2020 |  finance.yahoo.com
SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast
December 11, 2020 |  finance.yahoo.com
Stock Alert: SELLAS Life Sciences Hits New 52-week High
December 10, 2020 |  nasdaq.com
SELLAS Life Sciences EPS misses by $0.26
November 13, 2020 |  seekingalpha.com
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2020 Financial Results
November 13, 2020 |  finance.yahoo.com
SELLAS Receives IMPD Approval from the French Regulatory Authority for its Pivotal Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute Myeloid Leukemia
September 9, 2020 |  finance.yahoo.com
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2020 Financial Results
August 13, 2020 |  finance.yahoo.com
SELLAS Life Sciences Announces $9.2 Million Private Placement Priced At-The-Market
July 31, 2020 |  finance.yahoo.com
SELLAS Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update
May 14, 2020 |  finance.yahoo.com
SELLAS Releases Annual Letter to Shareholders
April 28, 2020 |  finance.yahoo.com
SELLAS Life Sciences Group Inc.
March 28, 2020 |  www.barrons.com
SELLAS Announces Positive Antigen-Specific Immune Response Data for Nelipepimut-S (NPS) in Women with Ductal Carcinoma In Situ (DCIS) of the Breast from Phase 2 VADIS Study
March 18, 2020 |  finance.yahoo.com
Stock Alert: Sellas Life Sciences Up 50% On Positive Result Of Leukemia Drug
February 26, 2020 |  markets.businessinsider.com
See More Headlines

MarketRank™

Overall MarketRank™

0.50 out of 5 stars

Medical Sector

1557th out of 2,019 stocks

Pharmaceutical Preparations Industry

657th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$8.45
+0.24 (+2.92 %)
(As of 04/13/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SLS News and Ratings via Email

Sign-up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











SELLAS Life Sciences Group (NASDAQ:SLS) Frequently Asked Questions

What stocks does MarketBeat like better than SELLAS Life Sciences Group?

Wall Street analysts have given SELLAS Life Sciences Group a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but SELLAS Life Sciences Group wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is SELLAS Life Sciences Group's next earnings date?

SELLAS Life Sciences Group is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for SELLAS Life Sciences Group.

How were SELLAS Life Sciences Group's earnings last quarter?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) released its earnings results on Tuesday, March, 23rd. The company reported ($0.28) EPS for the quarter. The business earned $1.90 million during the quarter.
View SELLAS Life Sciences Group's earnings history.

How has SELLAS Life Sciences Group's stock been impacted by Coronavirus?

SELLAS Life Sciences Group's stock was trading at $2.14 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SLS stock has increased by 294.9% and is now trading at $8.45.
View which stocks have been most impacted by COVID-19.

Who are SELLAS Life Sciences Group's key executives?

SELLAS Life Sciences Group's management team includes the following people:
  • Dr. Angelos M. Stergiou M.D., ScD h.c., Founder, Pres, CEO & Director (Age 45, Pay $962.5k)
  • Mr. John Thomas Burns CPA, CPA, VP of Fin. & Corp. Controller, Chief Accounting Officer and Principal Accounting Officer (Age 36, Pay $338.45k)
  • Ms. Barbara A. Wood, Exec. VP, Gen. Counsel & Sec. (Age 58, Pay $525.49k)
  • Mr. Martin G. Baum, Chief Operating Officer (Age 55)
  • Dr. Dragan Cicic, Sr. VP of Clinical Devel. (Age 58)
  • Dr. Christopher R. Shackleton, Director of Clinical and Bus. Operations
  • Mr. Jörg W. Breitkopf, Head of Clinical Operations
  • Mr. David D. Moser, VP of Legal Affairs

Who are some of SELLAS Life Sciences Group's key competitors?

Some companies that are related to SELLAS Life Sciences Group include Avadel Pharmaceuticals (AVDL), TherapeuticsMD (TXMD), Amryt Pharma (AMYT), Provention Bio (PRVB), XBiotech (XBIT), Akouos (AKUS), AC Immune (ACIU), RAPT Therapeutics (RAPT), Verona Pharma (VRNA), Altimmune (ALT), Flexion Therapeutics (FLXN), 89bio (ETNB), Forte Biosciences (FBRX), Fortress Biotech (FBIO) and Akebia Therapeutics (AKBA).
View all of SLS's competitors.

What is SELLAS Life Sciences Group's stock symbol?

SELLAS Life Sciences Group trades on the NASDAQ under the ticker symbol "SLS."

How do I buy shares of SELLAS Life Sciences Group?

Shares of SLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SELLAS Life Sciences Group's stock price today?

One share of SLS stock can currently be purchased for approximately $8.45.

How much money does SELLAS Life Sciences Group make?

SELLAS Life Sciences Group has a market capitalization of $127.47 million.

How many employees does SELLAS Life Sciences Group have?

SELLAS Life Sciences Group employs 7 workers across the globe.

What is SELLAS Life Sciences Group's official website?

The official website for SELLAS Life Sciences Group is www.sellaslifesciences.com.

Where are SELLAS Life Sciences Group's headquarters?

SELLAS Life Sciences Group is headquartered at 15 WEST 38TH STREET 10TH FLOOR, NEW YORK NY, 10018.

How can I contact SELLAS Life Sciences Group?

SELLAS Life Sciences Group's mailing address is 15 WEST 38TH STREET 10TH FLOOR, NEW YORK NY, 10018. The company can be reached via phone at 917 438 4353 or via email at [email protected]


This page was last updated on 4/14/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.